323 related articles for article (PubMed ID: 24439255)
1. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.
Barrett DM; Singh N; Liu X; Jiang S; June CH; Grupp SA; Zhao Y
Cytotherapy; 2014 May; 16(5):619-30. PubMed ID: 24439255
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
3. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
[TBL] [Abstract][Full Text] [Related]
4. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
5. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.
Barrett DM; Liu X; Jiang S; June CH; Grupp SA; Zhao Y
Hum Gene Ther; 2013 Aug; 24(8):717-27. PubMed ID: 23883116
[TBL] [Abstract][Full Text] [Related]
6. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
8. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
9. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
Front Immunol; 2022; 13():836549. PubMed ID: 35222427
[TBL] [Abstract][Full Text] [Related]
10. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
[TBL] [Abstract][Full Text] [Related]
11. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
13. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
Enblad G; Karlsson H; Gammelgård G; Wenthe J; Lövgren T; Amini RM; Wikstrom KI; Essand M; Savoldo B; Hallböök H; Höglund M; Dotti G; Brenner MK; Hagberg H; Loskog A
Clin Cancer Res; 2018 Dec; 24(24):6185-6194. PubMed ID: 30097433
[TBL] [Abstract][Full Text] [Related]
14. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of piggyBac-mediated anti-CD19 CAR-T cells after ex vivo expansion with aAPCs or magnetic beads.
Yang LR; Li L; Meng MY; Wang WJ; Yang SL; Zhao YY; Wang RQ; Gao H; Tang WW; Yang Y; Yang LL; Liao LW; Hou ZL
J Cell Mol Med; 2021 Jan; 25(2):686-700. PubMed ID: 33225580
[TBL] [Abstract][Full Text] [Related]
16. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
[TBL] [Abstract][Full Text] [Related]
17. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA
Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098
[TBL] [Abstract][Full Text] [Related]
18.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
19. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.
Liu X; Barrett DM; Jiang S; Fang C; Kalos M; Grupp SA; June CH; Zhao Y
Blood Cancer J; 2016 Jun; 6(6):e430. PubMed ID: 27258611
[TBL] [Abstract][Full Text] [Related]
20. Efficient derivation of chimeric-antigen receptor-modified T
Kranz E; Kuhlmann CJ; Chan J; Kim PY; Chen ISY; Kamata M
Front Immunol; 2022; 13():877682. PubMed ID: 35967430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]